14.02

4.37% -0.63

10 X Genomics Inc (TXG)

Overview News Price History Option Chain Financials Discussions Forecast

10 X Genomics Inc stock is traded at $14.02, with a volume of 1.77M. It is down -4.37% in the last 24 hours and down -9.79% over the past month. 10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Previous Close:

$14.65

Open:

$14.68

24h Volume:

1.77M

Relative Volume:

0.94

Market Cap:

$1.77B

Revenue:

$631.73M

Net Income/Loss:

$-239.78M

P/E Ratio:

-6.9406

EPS:

-2.02

Net Cash Flow:

$-33.45M

1W Performance:

-6.60%

1M Performance:

-9.79%

6M Performance:

-22.73%

1Y Performance:

-69.58%

1-Day Range:

$13.78

$15.20

1-Week Range:

$13.78

$15.20

52-Week Range:

$12.95

$51.22

10 X Genomics Inc Stock (TXG) Company Profile

Name

10 X Genomics Inc

Sector

Healthcare (1187)

Industry

Health Information Services (60)

Phone

(925) 401-7300

Address

6230 STONERIDGE MALL ROAD, PLEASANTON, CA

Employee

1,259

Twitter

@10xgenomics

Next Earnings Date

2024-10-31

Latest SEC Filings

TXG's Discussions on Twitter

Compare TXG with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TXG 10 X Genomics Inc	14.03	1.77B	631.73M	-239.78M	-33.45M	-2.02
VEEV Veeva Systems Inc	235.63	38.87B	2.66B	665.91M	1.08B	4.05
SOLV Solventum Corp	73.19	12.92B	8.26B	66.00M	1.17B	0.3682
DOCS Doximity Inc	78.93	10.88B	516.85M	174.11M	217.38M	0.87
TEM Tempus Ai Inc	68.25	10.23B	640.44M	-743.28M	-206.93M	-11.29
HQY Healthequity Inc	112.03	9.71B	1.15B	96.70M	-161.99M	1.09

10 X Genomics Inc Stock (TXG) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-03-24	Initiated	Leerink Partners	Outperform
Jul-22-24	Upgrade	Jefferies	Hold → Buy
Jul-18-24	Downgrade	JP Morgan	Overweight → Neutral
Jul-10-24	Downgrade	Deutsche Bank	Buy → Hold
Jun-27-24	Downgrade	Wolfe Research	Outperform → Peer Perform
Jun-25-24	Downgrade	Guggenheim	Buy → Neutral
Jun-03-24	Resumed	Jefferies	Hold
May-01-24	Downgrade	TD Cowen	Buy → Hold
Dec-14-23	Initiated	Guggenheim	Buy
Dec-13-23	Initiated	Wolfe Research	Outperform
Dec-12-23	Upgrade	BofA Securities	Underperform → Neutral
Jul-05-23	Resumed	JP Morgan	Overweight
May-10-23	Initiated	Barclays	Overweight
Mar-31-23	Initiated	Stephens	Overweight
Feb-02-23	Initiated	UBS	Neutral
Dec-14-22	Initiated	Deutsche Bank	Buy
Aug-18-22	Downgrade	Goldman	Neutral → Sell
Jul-25-22	Initiated	Canaccord Genuity	Buy
Jul-15-22	Downgrade	BofA Securities	Neutral → Underperform
Jul-15-22	Downgrade	William Blair	Outperform → Mkt Perform
Oct-15-21	Resumed	Cowen	Outperform
Sep-14-21	Downgrade	BofA Securities	Buy → Neutral
Mar-15-21	Initiated	William Blair	Outperform
Dec-02-20	Initiated	Goldman	Neutral
Sep-09-20	Initiated	Morgan Stanley	Overweight
Jul-10-20	Initiated	Stifel	Buy
Mar-05-20	Initiated	Guggenheim	Buy
Jan-07-20	Initiated	Citigroup	Buy
Oct-07-19	Initiated	BofA/Merrill	Buy
Oct-07-19	Initiated	Cowen	Outperform
Oct-07-19	Initiated	JP Morgan	Overweight
Sep-24-19	Initiated	Evercore ISI	Outperform

View All

10 X Genomics Inc Stock (TXG) Latest News

06:22 AM

10x Genomics (NASDAQ:TXG) shareholders have endured a 84% loss from investing in the stock three years ago - Simply Wall St

06:22 AM

01:41 AM

China Universal Asset Management Co. Ltd. Acquires New Position in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

01:41 AM

Feb 06, 2025